Loading clinical trials...
Loading clinical trials...
A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY OF A 6-VALENT OspA-BASED LYME DISEASE VACCINE (VLA15) IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE
Conditions
Interventions
VLA15
Normal Saline
Locations
65
United States
UAB Child Health Research Unit (CHRU)
Birmingham, Alabama, United States
University of Alabama at Birmingham - School of Medicine
Birmingham, Alabama, United States
Lakeview Clinical Research
Guntersville, Alabama, United States
Coast Clinical Research, LLC
Bellflower, California, United States
Apex Research Group LLC
Fair Oaks, California, United States
New England Research Associates
Bridgeport, Connecticut, United States
Start Date
December 12, 2022
Primary Completion Date
July 21, 2025
Completion Date
July 21, 2025
Last Updated
September 15, 2025
NCT00001539
NCT00028080
NCT06511050
NCT04402086
NCT06785402
NCT04806620
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions